echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > IMS 2022 Voice of China 1q21 acquisition is an independent poor prognostic factor in newly diagnosed multiple myeloma patients

    IMS 2022 Voice of China 1q21 acquisition is an independent poor prognostic factor in newly diagnosed multiple myeloma patients

    • Last Update: 2022-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Edited by Yimaitong, please do not reprint without authorization



    1q21 gain (1q21 gain) ismultiple myeloma(MM) is a common abnormal karyotype, and its positive rate in Chinese MM patients is high, reaching 40%-60%



    Research methods


    The study included 248 NDMM patients from the First Affiliated Hospital of Soochow University



    Research result


    Occurs in patients with 1q acquisition (54.



    Analysis conclusion


    Patients with 1q21 acquisition had significant visceral organ damage and higher tumor burden



    Reference source:

    Chengcheng Fu, et al.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.